Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Rafael Holdings, Inc. on September 24, 2021, regarding a significant corporate event. The Company is a Delaware corporation with its principal executive offices in Newark, New Jersey. Its Class B common stock trades on the New York Stock Exchange under the symbol "RFL".
Key Financial Metrics and Transaction Details
The filing details a new Line of Credit Loan Agreement entered into with Rafael Pharmaceuticals, Inc. ("Rafael Pharma"), a subsidiary in which the Company holds a 51% equity interest (41% on a fully diluted basis). Key financial terms include:
- Total Loan Commitment: $25,000,000.
- Funding Schedule: $1.9 million advanced on September 24, 2021; the remaining balance funded on October 1, 2021.
- Interest Rate: 9% per annum, capitalized and added to the principal, due upon maturity.
- Maturity Date: The later of February 1, 2022 (expected End Date of the Merger Agreement) or 135 days following the termination of the Merger Agreement.
- Debt Seniority: Pari passu with existing indebtedness of Rafael Pharma.
Material Changes and Related Party Transactions
This filing represents a material change in the Company's capital structure and related party relationships. The transaction involves significant related party interests: Ameet Mallik, the Company's CEO, serves as Chairman of Rafael Pharma's Board, and Howard Jonas, the Company's Chairman, owns interests in Rafael Pharma. The funds are restricted for use by Rafael Pharma in accordance with a budget approved by the Company.
Outlook, Risks, and Contingencies
The loan agreement is heavily contingent upon the status of the previously disclosed Merger Agreement between the Company and Rafael Pharma.
- Conversion Rights: Upon triggering events, including the termination of the Merger Agreement, the Company may convert outstanding loan amounts into Rafael Pharma equity securities based on the equity value at the time of conversion.
- Repayment/Repurchase Option: Rafael Pharma retains the right to repay the outstanding balance or repurchase converted securities within 120 days.
- Events of Default: Failure to comply with obligations under the Merger Agreement constitutes an event of default.
- Additional Indebtedness: Rafael Pharma is prohibited from incurring additional debt, except for up to $10 million of debt that is pari passu with this agreement, subject to the Company's right of first refusal.
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a current report focused on a specific event rather than a periodic financial statement.
Key Facts for Investor Verification
- Verify the current status of the Merger Agreement between Rafael Holdings and Rafael Pharma, as the loan maturity and default provisions are tied to it.
- Confirm the exact equity ownership percentage of Rafael Holdings in Rafael Pharma on a fully diluted basis, noting the exclusion of certain warrants.
- Monitor the utilization of the $25 million credit line and the specific budget approved by the Company for Rafael Pharma's operations.
- Assess the potential dilution impact if the loan is converted to equity following a termination of the Merger Agreement.